



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

August 27, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – August 25, 2021

TOTAL Cases Reported Since 1/22/20

38,341,339

NEW Cases Reported to CDC on 8/25/21

164,952

Change in 7-Day Case Average


+2.8%

Current 7-Day Case Average (8/19/21 - 8/25/21)

142,006

Prior 7-Day Case Average (8/12/21 - 8/18/21)

138,087



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – August 24, 2021

Patients Currently Hospitalized with COVID on 8/24/21

89,770

New Admissions on 8/24/21

12,863

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


+5.7%

Current 7-Day Average of New Admissions (8/18/21 - 8/24/21)

12,297

Prior 7-Day Average of New Admissions (8/11/21 - 8/17/21)

11,637



Daily Change in COVID-19 Deaths, US

January 22, 2020 – August 25, 2021

TOTAL Deaths Reported Since 1/22/2020

631,440

NEW Deaths Reported to CDC on 8/25/21

1,229

Change in 7-Day Death Average

+11.0%

Current 7-Day Death Average (8/19/21 - 8/25/21)


864

Prior 7-Day Death Average (8/12/21 - 8/18/21)

779

Forecasted Total Deaths by 9/18/21

651,000 to 680,000



COVID-19 Vaccine Efficacy and Safety in Adolescents





The
New England
Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Volume 385 July 15, 2021 Number 3

Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents

RW Frenck, Jr., WC Gruber et al. for the C4591001
Clinical Trial Group

- N= 2,260 adolescents 12 to 15 years
- Favorable safety profile, produced a greater immune response than in young adults
- Vaccine efficacy = 100%



The
New England
Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Published online August 11, 2021

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

K Ali, R McPhee et al.

- TeenCOVE study of Moderna vaccine; n = 3,732 adolescents 12 to 17 years
- 100% vaccine efficacy against COVID-19 14 days after 2nd dose (small number of endpoints)
- No serious adverse events related to vaccine



Pfizer-BioNTech COVID-19 Vaccine (BNT162b2, Comirnaty®) for Adolescents

- **FDA issued an Emergency Use Authorization (EUA) for use in persons aged ≥ 16 years on December 11, 2020**
- **EUA was expanded to include adolescents aged 12-15 years on May 10, 2021, based on results from a Phase 3 clinical trial**
- **Vaccine fully licensed by FDA for persons aged ≥ 16 years on August 23, 2021**
 - **Vaccine continues to be available under EUA for adolescents 12 through 15 years of age**



- **Moderna requested EUA for mRNA-1273 vaccine for adolescents ages 12 to 17 on June 10, 2021; FDA decision pending**



Safety of COVID-19 Vaccines in Adolescents

- **Mild Local and Systemic Reactions are Common Among Adolescents**

- **Serious Adverse Events are Rare**



Weekly

July 9, 2021

Vol. 70 No. 27

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021

Weekly

August 6, 2021

Vol. 70 No. 31

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years – United States, December 14, 2020–July 16, 2021

Weekly

August 13, 2021

Vol. 70 No. 32

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices – United States, July 2021

Reasons for Adolescents to Be Vaccinated Against COVID-19

- COVID-19 vaccines are safe, effective, convenient..... and free
- Protect yourself from COVID-19
- Help protect family members, friends, classmates, teachers and other important people your life
 - Some of them may be especially vulnerable to COVID-19 complications, and you may not know it





THE WHITE HOUSE
WASHINGTON

WH.GOV